Smoking Addiction - Pipeline Review, H2, Pharmaceutical 2016
Albany, New York, Jan 19,2017
"Smoking
Addiction - Pipeline Review, H2 2016"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Smoking Addiction Pipeline Review, H2 2016, provides
an overview of the Smoking Addiction (Central Nervous System)
pipeline landscape.
In
smoking addiction, people experience an uncontrollable dependence on
cigarettes, which on stopping will cause severe mental, emotional or
physical reactions. People addicted to smoking develop tolerance to
nicotine. Nicotine acts on acetylcholine receptors causing the body
to react to nicotine at these receptors in the same manner as it
responds to acetylcholine
This
leads to alterations in the activity and physiological functions of
many brain systems. This causes structural and functional changes in
the brains of smokers. Upon sudden nicotine withdrawal, the brain and
other parts of the body get disturbed, leading to a condition called
withdrawal syndrome. The body usually takes time to function in the
absence of nicotine. The effects of smoking withdrawal stem from the
lack of nicotine that can be overcome by nicotine replacement
therapies such as the use of nicotine patch or nicotine chewing gum.
*
Report Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Smoking Addiction Pipeline Review, H2 2016, provides comprehensive
information on the therapeutics under development for Smoking
Addiction (Central Nervous System), complete with analysis by stage
of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The
Smoking Addiction (Central Nervous System) pipeline guide also
reviews of key players involved in therapeutic development for
Smoking Addiction and features dormant and discontinued projects. The
guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5,
6, 7, 4 and 2 respectively. Similarly, the Universities portfolio in
Preclinical and Discovery stages comprises 2 and 1 molecules,
respectively.
Smoking
Addiction (Central Nervous System) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage. The guide
is built using data and information sourced from Global Markets
Directs proprietary databases, company/university websites, clinical
trial registries, conferences, SEC filings, investor presentations
and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic
tracking processes ensure that the most recent developments are
captured on a real time basis.
*
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Smoking Addiction (Central Nervous System).
-
The pipeline guide reviews pipeline therapeutics for Smoking
Addiction (Central Nervous System) by companies and
universities/research institutes based on information derived from
company and industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in Smoking
Addiction (Central Nervous System) therapeutics and enlists all their
major and minor projects.
-
The pipeline guide evaluates Smoking Addiction (Central Nervous
System) therapeutics based on mechanism of action (MoA), drug target,
route of administration (RoA) and molecule type.
-
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
-
The pipeline guide reviews latest news related to pipeline
therapeutics for Smoking Addiction (Central Nervous System)
*
Reasons to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Smoking Addiction (Central Nervous System).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Smoking Addiction (Central Nervous System) pipeline depth and focus
of Indication therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Comments
Post a Comment